Postchemotherapy Retroperitoneal Surgery Remains Necessary in Patients With Nonseminomatous Testicular Cancer and Minimal Residual Tumor Masses
- 1 September 2003
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (17), 3310-3317
- https://doi.org/10.1200/jco.2003.03.184
Abstract
Purpose: To determine preoperative parameters that predict the histology of specimens obtained by retroperitoneal lymph node dissection (RPLND) in patients with nonseminomatous germ cell cancer (NSGCT) whose residual mass was ≤ 20 mm in diameter after modern cisplatin-based induction chemotherapy. Patients and Methods: Eighty-seven patients with metastatic NSGCT underwent RPLND after having received cisplatin- or carboplatin-based induction chemotherapy. In all patients, the largest diameter of the residual mass on the transaxial plane was ≤ 20 mm, as assessed by abdominal computed tomography (CT) immediately before RPLND. Results: Complete fibrosis or necrosis was found in 58 patients (67%), teratoma was found in 23 patients (26%), and vital malignant germ cell tumor was found in six patients (7%), including one patient with rhabdomyosarcoma in the RPLND specimen. In five of the six latter patients, the residual lesion was ≤ 10 mm at pre-RPLND CT. No pre- or postchemotherapy clinical or radiologic parameter was identified that significantly predicted the histology of the residual mass. Conclusion: One third of retroperitoneal postchemotherapy lesions ≤ 20 mm contained residual vital tumor tissue, despite modern chemotherapy regimens. Therefore, postchemotherapy RPLND remains necessary in patients with minimal-size residual lesions to facilitate easy and safe follow-up and initiate additional therapy as early as possible, thus avoiding recurrences.This publication has 32 references indexed in Scilit:
- Metastatic nonseminomatous germ cell tumors of the testisCancer, 2002
- Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissectionBritish Journal of Cancer, 1999
- Retroperitoneal lymphadenectomy for post‐chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient?BJU International, 1998
- Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors.Journal of Clinical Oncology, 1997
- Complications of the post‐chemotherapy resection of retroperitoneal residual tumour mass in patients withBJU International, 1997
- Nerve Sparing Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Testicular CancerJournal of Urology, 1996
- Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.Journal of Clinical Oncology, 1995
- Original Articles: Testis Cancer: Complications of Post-Chemotherapy Retroperitoneal Lymph Node DissectionJournal of Urology, 1995
- Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumorsCancer, 1994
- Asymmetrical Autonomic Dysfunction of the Feet After Retroperitoneal Surgery in Patients with Testicular Cancer: 2 Case ReportsJournal of Urology, 1992